PMID- 19381454
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20220309
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 4
IP  - 2
DP  - 2009 Apr
TI  - The emerging safety profile of mTOR inhibitors, a novel class of anticancer 
      agents.
PG  - 135-42
LID - 10.1007/s11523-009-0107-z [doi]
AB  - Mammalian target of rapamycin (mTOR) has emerged as an important target for 
      cancer therapy. Rapamycin has a distinct, well-documented toxicity profile and 
      most of the toxicity data has been reported in patients with organ 
      transplantation. Newer mTOR inhibitors have slightly different pharmacokinetic 
      properties, yet they present toxicity profiles similar to rapamycin. Most of 
      these toxicities are mild to moderate in severity and can be managed clinically 
      by dose modification and supportive measures. Mucositis and pneumonitis are the 
      most commonly reported toxicities, but they rarely lead to treatment 
      discontinuation. Pathogenesis of pneumonitis is uncertain, but various hypotheses 
      have been suggested, including cell-mediated immune response to the drug.
FAU - Sankhala, Kamalesh
AU  - Sankhala K
AD  - Institute for Drug Development, Cancer Therapy and Research Center at the 
      University of Texas Health Science Center, San Antonio, TX 78229, USA.
FAU - Mita, Alain
AU  - Mita A
FAU - Kelly, Kevin
AU  - Kelly K
FAU - Mahalingam, Devalingam
AU  - Mahalingam D
FAU - Giles, Francis
AU  - Giles F
FAU - Mita, Monica
AU  - Mita M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090421
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Drug Hypersensitivity/*immunology
MH  - Graft Rejection/drug therapy
MH  - Humans
MH  - Mucositis/chemically induced
MH  - Neoplasms/*drug therapy/pathology
MH  - Organ Transplantation
MH  - Pneumonia/*chemically induced/diagnosis/immunology/physiopathology
MH  - Prognosis
MH  - Protein Kinases/*metabolism
MH  - Sirolimus/*adverse effects/therapeutic use
MH  - TOR Serine-Threonine Kinases
MH  - Th1 Cells/immunology
MH  - Th2 Cells/immunology
MH  - Treatment Outcome
RF  - 41
EDAT- 2009/04/22 09:00
MHDA- 2009/08/21 09:00
CRDT- 2009/04/22 09:00
PHST- 2009/02/18 00:00 [received]
PHST- 2009/03/27 00:00 [accepted]
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
AID - 10.1007/s11523-009-0107-z [doi]
PST - ppublish
SO  - Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 
      21.